To this end, we first examined whether Lic5, a mAb targeting the first two of the seven extracellular domains of CDH17 (Fig. S1) would attenuate the β-catenin signaling in metastatic human HCC cell line. The gene discussed is CDH17; the disease is hepatocellular carcinoma.